Neuroendocrine carcinoma and mixed neuroendocrine‒non-neuroendocrine neoplasm of the stomach: a clinicopathological and exome sequencing study

Hum Pathol. 2021 Apr:110:1-10. doi: 10.1016/j.humpath.2020.12.008. Epub 2021 Jan 21.

Abstract

The gene mutation profiles of gastric neuroendocrine neoplasms are incompletely understood. The purpose of this study was to characterize the molecular pathology of poorly differentiated neuroendocrine carcinoma (NEC) and mixed neuroendocrine‒non-neuroendocrine neoplasm (MiNEN) of the stomach. Surgical cases of gastric NEC (n = 7) and MiNEN (n = 6) were examined by clinical review, immunohistochemistry, microsatellite instability (MSI) analysis and whole-exome sequencing. NEC cases consisted of small- (n = 2) and large-cell types (n = 4). All cases of MiNEN were histologically composed of large-cell type NEC and tubular adenocarcinoma. Whole-exome sequencing analysis detected recurrent mutations in TP53 in 8 cases (62%), and they were more frequently observed in MiNEN than in NEC (100% vs. 29%). Frameshift mutations of APC were observed in two cases of MiNEN. One case of large-cell type NEC had a frameshift mutation with loss of heterozygosity in RB1. The other mutated genes (e.g., ARID1 and KRAS) were detected in a single case each. A high level of MSI was confirmed in one case of MiNEN, which harbored mutations in two well-differentiated neuroendocrine tumor (NET)-related genes (MEN1 and ATRX1). In cases of MiNEN, two histological components shared mutations in TP53, APC and ZNF521, whereas alterations in CTNNB1, KMT2C, PTEN and SPEN were observed in neuroendocrine components only. In conclusion, TP53 is a single, frequently mutated gene in gastric NEC and MiNEN, and alterations in other genes are less common, resembling the mutation profiles of gastric adenocarcinomas. Gene mutations frequently observed in well-differentiated NET were uncommon but not entirely exclusive.

Keywords: Adenoendocrine carcinoma; Gastric cancer; MEN1; Neuroendocrine; TP53.

MeSH terms

  • Adenocarcinoma / pathology
  • Aged
  • Aged, 80 and over
  • Biomarkers, Tumor / analysis
  • Biomarkers, Tumor / genetics*
  • Carcinoma, Neuroendocrine* / genetics
  • Carcinoma, Neuroendocrine* / pathology
  • Exome / genetics
  • Exome Sequencing / methods
  • Humans
  • Male
  • Middle Aged
  • Mutation / genetics
  • Neuroendocrine Tumors* / genetics
  • Neuroendocrine Tumors* / pathology
  • Pancreatic Neoplasms / pathology
  • Stomach / pathology
  • Stomach Neoplasms* / genetics
  • Stomach Neoplasms* / pathology

Substances

  • Biomarkers, Tumor